These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 3306455)

  • 1. Iatrogenic Creutzfeldt-Jakob disease.
    Rappaport EB
    Neurology; 1987 Sep; 37(9):1520-2. PubMed ID: 3306455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iatrogenic Creutzfeldt-Jakob disease.
    Kobayashi A; Kitamoto T; Mizusawa H
    Handb Clin Neurol; 2018; 153():207-218. PubMed ID: 29887137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iatrogenic Creutzfeldt-Jakob disease. Lessons from cases secondary to extracted growth hormone in France].
    Billette de Villemeur T; Pradel A
    Transfus Clin Biol; 1994; 1(5):333-7. PubMed ID: 7812459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the risk of iatrogenic transmission of Creutzfeldt-Jakob disease in the UK.
    Hall V; Brookes D; Nacul L; Gill ON; Connor N;
    J Hosp Infect; 2014 Sep; 88(1):22-7. PubMed ID: 25082752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.
    Brown P; Brandel JP; Preece M; Sato T
    Neurology; 2006 Aug; 67(3):389-93. PubMed ID: 16855204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients.
    Huillard d'Aignaux J; Alpérovitch A; Maccario J
    Am J Epidemiol; 1998 Mar; 147(6):597-604. PubMed ID: 9521187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creutzfeldt-Jakob disease risk in Slovak recipients of human pituitary growth hormone.
    Mitrova E; Belay G
    Bratisl Lek Listy; 1999 Apr; 100(4):187-91. PubMed ID: 10914140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human prion diseases: surgical lessons learned from iatrogenic prion transmission.
    Bonda DJ; Manjila S; Mehndiratta P; Khan F; Miller BR; Onwuzulike K; Puoti G; Cohen ML; Schonberger LB; Cali I
    Neurosurg Focus; 2016 Jul; 41(1):E10. PubMed ID: 27364252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Infectious prion disease: CJD with dura mater transplantation].
    Sato T
    Rinsho Shinkeigaku; 2003 Nov; 43(11):870-2. PubMed ID: 15152489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts -- Japan, January 1979-May 1996.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Nov; 46(45):1066-9. PubMed ID: 9385874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease.
    Collinge J; Palmer MS; Dryden AJ
    Lancet; 1991 Jun; 337(8755):1441-2. PubMed ID: 1675319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar genetic susceptibility in iatrogenic and sporadic Creutzfeldt-Jakob disease.
    Deslys JP; Marcé D; Dormont D
    J Gen Virol; 1994 Jan; 75 ( Pt 1)():23-7. PubMed ID: 8113733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iatrogenic Creutzfeldt-Jakob disease, final assessment.
    Brown P; Brandel JP; Sato T; Nakamura Y; MacKenzie J; Will RG; Ladogana A; Pocchiari M; Leschek EW; Schonberger LB
    Emerg Infect Dis; 2012 Jun; 18(6):901-7. PubMed ID: 22607808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
    Boyd A; Klug GM; Schonberger LB; McGlade A; Brandel JP; Masters CL; Collins SJ
    Med J Aust; 2010 Sep; 193(6):366-9. PubMed ID: 20854243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human growth hormone and Creutzfeldt-Jakob disease.
    Zekauskas S; Boggs MB; Wilson DP
    J Okla State Med Assoc; 1990 Sep; 83(9):447-8. PubMed ID: 2280278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone.
    Purro SA; Farrow MA; Linehan J; Nazari T; Thomas DX; Chen Z; Mengel D; Saito T; Saido T; Rudge P; Brandner S; Walsh DM; Collinge J
    Nature; 2018 Dec; 564(7736):415-419. PubMed ID: 30546139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creutzfeldt-Jakob disease after receipt of a previously unimplicated brand of dura mater graft.
    Hannah EL; Belay ED; Gambetti P; Krause G; Parchi P; Capellari S; Hoffman RE; Schonberger LB
    Neurology; 2001 Apr; 56(8):1080-3. PubMed ID: 11320182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide.
    Brandel JP; Peckeu L; Haïk S
    Transfus Clin Biol; 2013 Sep; 20(4):395-7. PubMed ID: 23587616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue safety in view of CJD and variant CJD.
    Pauli G
    Cell Tissue Bank; 2005; 6(3):191-200. PubMed ID: 16151959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creutzfeldt-Jakob disease in a recipient of a dura mater graft processed in the US: cause or coincidence?
    Dobbins JG; Belay ED; Malecki J; Buck BE; Bell M; Cobb J; Schonberger LB
    Neuroepidemiology; 2000; 19(2):62-6. PubMed ID: 10686530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.